Cytokine dynamics in vitiligo: the roles of interleukin-10 and interleukin-17

Abstract

Aim:Vitiligo is an autoimmune skin disorder characterized by melanocyte destruction and progressive depigmentation. Cytokine imbalance plays a key role in its pathogenesis. This study aims to evaluate and compare serum levels of the anti-inflammatory cytokine interleukin-10 (IL-10) and the pro-inflammatory cytokine IL-17 in vitiligo patients and healthy individuals, to explore their potential as biomarkers of disease activity.

Methods:A total of 60 vitiligo patients and 40 age- and sex-matched healthy controls were recruited. Serum concentrations of IL-10 and IL-17 were measured using enzyme-linked immunosorbent assay (ELISA). Disease severity and duration were also assessed in relation to cytokine levels.

Results:Vitiligo patients showed significantly lower IL-10 levels (9.37 ± 0.17 pg/mL) compared to controls (11.38 ± 0.22 pg/mL,P < 0.01), and significantly higher IL-17 levels (326.48 ± 5.49 pg/mL) compared to controls (270.47 ± 8.48 pg/mL, P < 0.01).

Conclusions:These findings suggest an inflammatory cytokine imbalance in vitiligo, characterized by decreased IL-10 and elevated IL-17 levels. The significant correlation of IL-17 with disease progression supports its role as a potential biomarker of disease activity. Targeting cytokine pathways may offer new directions for immunomodulatory treatment strategies in vitiligo.

Keywords

Vitiligo / inflammatory / cytokine / IL-10 / IL-17

References

[1] Wang X, Fan J, He K, Chen J, Li S. Serum cytokine profiles predict response to systemic glucocorticoid in active vitiligo. Postepy Derm Alergol. 2024; 41: 189-96.

[2] Ismail IB, Bhat YJ, Islam MSU. Treatment Advances in Vitiligo: An Updated Review. Dermatol Pract Concept. 2025; 15: 4600.

[3] Custurone P, Di Bartolomeo L, Irrera N, Borgia F, Altavilla D, Bitto A, et al. Role of Cytokines in Vitiligo: Pathogenesis and Possible Targets for Old and New Treatments. Int J Mol Sci. 2021; 22: 11429.

[4] Yang Y, Du Y, Cui B. Polyphenols targeting multiple molecular targets and pathways for the treatment of vitiligo. Front Immunol. 2024; 15: 1387329.

[5] Shradha K, Gaikwad S. A comprehensive overview of vitiligo. Int J Sci R Tech. 2025; 2: 544-55.

[6] Beyzaee AM, Goldust M, Patil A, Rokni GR, Beyzaee S. The role of cytokines and vitamin D in vitiligo pathogenesis. J Cosmet Dermatol. 2022; 21: 6314-25.

[7] Kądziela M, Kutwin M, Karp P, Woźniacka A. Role of cytokines and chemokines in vitiligo and their therapeutic implications. J Clin Med. 2024; 13: 4919.

[8] Propper DJ, Balkwill FR. Harnessing cytokines and chemokines for cancer therapy. Nat Rev Clin Oncol. 2022; 19: 237-53.

[9] Marchioro HZ, Silva de Castro CC, Fava VM, Sakiyama PH, Dellatorre G, Miot HA. Update on the pathogenesis of vitiligo. An Bras Dermatol. 2022; 97: 478-90.

[10] Xerfan EMS, Andersen ML, Tufik S, Facina AS, Tomimori J. The impact on the quality of life and sleep complaints in a vitiligo sample and the influence of inflammatory cytokines in the interaction between vitiligo and sleep. Cytokine. 2024; 176: 156493.

[11] Liu C, Liu X, Xin H, Li X. A Mendelian randomization study on the causal effects of circulating cytokines on the risk of vitiligo. Front Med (Lausanne). 2024; 11: 1375339.

[12] Hlača N, Žagar T, Kaštelan M, Brajac I, Prpić-Massari L. Current concepts of vitiligo immunopathogenesis. Biomedicines. 2022; 10: 1639.

[13] Abdulkhaliq RJ, Mohammed S, Abbas AAH. The role of some cytokines in women with Recurrent Abortion in Iraqi Women. Pak J Med Health Sci. 2017; 11: 496-502.

[14] Gomes IA, de Carvalho FO, de Menezes AF, Almeida FM, Shanmugam S, de Souza Siqueira Quintans J, et al. The role of interleukins in vitiligo: a systematic review. J Eur Acad Dermatol Venereol. 2018; 32: 2097-111.

[15] Hamad AA, Mustafa HM, Mohsein OA. Detection of the levels of immune cytokines (IL4, IL5, TNF-α) in school-age and preschoolers with an Ascaris lumbricoides infection . J Parasit Dis. 2024; 48: 782-7.

[16] Picone V, Coronella L, Scalvenzi M, Patruno C, Lizzi L, Cimmino M, et al. Potential future biologic therapies for the treatment of vitiligo: focus on phase 2 and 3. Expert Rev Clin Immunol. 2025; 21: 711- 21.

[17] Chen Y, Zhan JY, Gao S, Li YR, Wu YF. Research progress of microbiome and pathogenesis of vitiligo. Life Res. 2021; 4: 13.

[18] Matarrese P, Puglisi R, Mattia G, Samela T, Abeni D, Malorni W. An overview of the biological complexity of vitiligo. Oxid Med Cell Longev. 2024; 2024: 3193670.

[19] Saleh RO, Mahmood LA, Mohammed MA, Al-Rawi KF, Al-Hakeim HK. Use of some bone-related cytokines as predictors for rheumatoid arthritis severity by neural network analysis. Russ J Infect Immun. 2023; 13: 147-55.

[20] Yasmin TM, Aya BY, Amal H, Amira KA, Ahmed GS. Serum interleukin-22 and C-reactive protein in patients with vitiligo: A case-control study on 35 Egyptian patients. Egypt J Dermatol Venerol. 2021; 41: 32-7.

[21] Liang X, Guo F, Fan Q, Cai X, Wang J, Chen J, et al. Healthy lifestyle choices: new insights into vitiligo management. Front Immunol. 2024; 15: 1440705.

[22] Faraj S, Kemp EH, Gawkrodger DJ. Patho-immunological mechanisms of vitiligo: the role of the innate and adaptive immunities and environmental stress factors. Clin Exp Immunol. 2022; 207: 27-43.